Oweida et al. used a preclinical murine model of HNSCC and showed that concurrent administration of RT, inhibitors against immune checkpoints PD-L1 and T-cell immunoglobulin mucin-3 (TIM-3) and a monoclonal anti-CD25 antibody led to a more durable therapeutic response and tumor regression as compared to treatment with RT in combination only with anti-PD-L1/anti-TIM-3. Here, HAVCR2 is linked to head and neck squamous cell carcinoma.